Quick Answer
Yubo International Biotech Ltd reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
Yubo International Biotech Ltd Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.01 | +50.0% |
| 2024 | -$0.02 | +80.0% |
| 2023 | -$0.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | +100.0% | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | +100.0% |
| September 30, 2024 | -$0.01 | — | — |
| June 30, 2024 | $0.00 | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
- Yubo International Biotech Ltd showed an increase of +50.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Yubo International Biotech Ltd’s diluted eps has grown by 90.0% (from $0.10 per share (loss) to $0.01 per share (loss)).
- The most recent figure is from Yubo International Biotech Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: